uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy
Open accessThe DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.
Abstract
// Miguel Angel Pavón 1,2,3 , Irene Arroyo-Solera 1,3 , Maria Virtudes Céspedes 1,3 , Isolda Casanova 1,3 , Xavier León 3,4 and Ramón Mangues 1,3 1 Grupo d’Oncogènesi i Antitumorals, lnstitut d’Investigacions Biomèdiques Sant Pau (IIB-Sant Pau), Barcelona, Spain 2 Infections and Cancer Unit, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO) and Bellvitge Institute of Biomedical Research (IDIBELL), Barcelona, Spain 3 Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomecidicina (CIBER-BBN), Barcelona, Spain 4 Department of Otorrinolaryngology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain Correspondence to: Ramón Mangues, email: // Xavier León, email: // Keywords : head and neck cancer, uPA, uPAR, SERPINE1, prognosis Received : May 05, 2016 Accepted : June 13, 2016 Published : June 30, 2016 Abstract There is strong evidence supporting the role of the plasminogen activator system in head and neck squamous cell carcinoma (HNSCC), particularly of its uPA (urokinase plasminogen activator) / uPAR (urokinase plasminogen activator receptor) and SERPINE1 components. Overexpression of uPA/uPAR and SERPINE1 enhances tumor cell migration and invasion and plays a key role in metastasis development, conferring poor prognosis. The apparent paradox of uPA/uPAR and its inhibitor SERPINE1 producing similar effects is solved by the identification of SERPINE1 activated signaling pathways independent of uPA inhibition. Both uPA/uPAR and SERPINE1 are directly linked to the induction of epithelial-to-mesenchymal transition, the acquisition of stem cell properties and resistance to antitumor agents. The aim of this review is to provide insight on the deregulation of these proteins in all these processes. We also summarize their potential value as prognostic biomarkers or potential drug targets in HNSCC patients. Concomitant overexpression of uPA/uPAR and SERPINE1 is associated with a higher risk of metastasis and could be used to identify patients that would benefit from an adjuvant treatment. In the future, the specific inhibitors of uPA/uPAR and SERPINE1, which are still under development, could be used to design new therapeutic strategies in HNSCCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672 · cited 1×
“SERPINE1 is directly connected with the epithelialmesenchymal transition (EMT) and the acquisition of stemness, two biological processes that are essential to control the transition from the proliferative to the invasive tumor phenotype [60, 93-97].”
BackgroundSignet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T., Chang, J., Markman, M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273
The molecular biology of head and neck cancer
Leemans, C. R., Braakhuis, B. J. M., & Brakenhoff, R. H. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2982 · Cited by 2,524
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Yu, M., Bardia, A., Wittner, B. S., Stott, S. L., Smas, M. E., Ting, D. T., Isakoff, S. J., Ciciliano, J. C., Wells, M. N., Shah, A. M., et al. (2013) · Science · doi:10.1126/science.1228522 · Cited by 2,476 · cited 2×
“In this sense, SERPINE1 overexpression has been observed in circulating tumor cells from breast cancer patients showing EMT-like features [97].”
BackgroundThe urokinase-type plasminogen activator system in cancer metastasis: A review
Andreasen, P. A., Kjøller, L., Christensen, L., & Duffy, M. J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970703)72:1<1::aid-ijc1>3.0.co;2-z · Cited by 1,546 · cited 5×
“Kallikrein, T cell-associated serine proteinase, cathepsin B, cathepsin L, nerve growth factor-γ, human mast cell tryptase and prostate specific antigen are other proteinases that can also catalyze “in vitro” the conversion of pro-uPA [12].”
BackgroundInfluentialuPAR: a versatile signalling orchestrator
Blasi, F., & Carmeliet, P. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm977 · Cited by 1,223 · cited 3×
“com/oncotarget though the activation of several metalloproteinases [14].”
BackgroundEpithelial–mesenchymal plasticity in carcinoma metastasis
Tsai, J. H., & Yang, J. (2013) · Genes & Development · doi:10.1101/gad.225334.113 · Cited by 1,136 · cited 1×
“Changes in cell adhesion and cytoskeletal remodeling, experienced during the EMT-process, increase tumor cell plasticity and drug resistance, effects that correlate with an increase in the expression of uPAR and SERPINE1 [106, 107].”
BackgroundRegulation of cell signalling by uPAR
Smith, H. W., & Marshall, C. J. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2821 · Cited by 960 · cited 1×
“uPAR can also promote the activation of the Ras-MAPK, Fak, Src and Rac and the PI3K-Akt pathways that have a significant effect on tumor cell migration [38].”
BackgroundThe plasminogen activation system in tumor growth, invasion, and metastasis
Andreasen, P. A., Egelund, R., & Petersen, H. H. (2000) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s000180050497 · Cited by 943 · cited 3×
“SERPINE1 inhibits the urokinase-type plasminogen (uPA) and tissue-type plasminogen activator (tPA), which in turn, reduce the conversion of plasminogen to the active protease plasmin [21].”
BackgroundNotch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation
Rangarajan, A. (2001) · The EMBO Journal · doi:10.1093/emboj/20.13.3427 · Cited by 866 · cited 1×
“Notch signaling is a crucial regulator of stem cell renewal and promotes terminal differentiation of keratinocytes through the expression of p21 and caspase-3 [103-105].”
BackgroundMolecular classification of head and neck squamous cell carcinomas using patterns of gene expression
Chung, C. H., Parker, J. S., Karaca, G., Wu, J., Funkhouser, W. K., Moore, D., Butterfoss, D., Xiang, D., Zanation, A., Yin, X., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00112-6 · Cited by 678
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
Bajou, K., Noël, A., Gerard, R. D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N. E., Carmeliet, P., Collen, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0898-923 · Cited by 677 · cited 1×
“SERPINE1 may also contribute to tumor aggressiveness by promoting tumor angiogenesis [67, 68].”
BackgroundKortlever, R. M., Higgins, P. J., & Bernards, R. (2006) · Nature Cell Biology · doi:10.1038/ncb1448 · Cited by 637 · cited 1×
“Its expression could also be modulated by several transcription factors such as SP1, AP1, SMAD proteins, TGF-β1, and p53 [44-46].”
BackgroundGhiso, J. A. A., Kovalski, K., & Ossowski, L. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.147.1.89 · Cited by 549 · cited 1×
“uPA and uPAR have been associated with an increase in the growth of head and neck cancer cells and with the activation of FAK and ERK1/2 signaling [30, 31].”
BackgroundRoepman, P., Wessels, L. F. A., Kettelarij, N., Kemmeren, P., Miles, A. J., Lijnzaad, P., Tilanus, M. G. J., Koole, R., Hordijk, G.-J., van der Vliet, P. C., et al. (2005) · Nature Genetics · doi:10.1038/ng1502 · Cited by 517 · cited 1×
“In microarray gene expression studies, SERPINE1 expression has been identified as a HNSCC marker [109, 111, 121-123].”
BackgroundEvolving role of uPA/uPAR system in human cancers
Dass, K., Ahmad, A., Azmi, A. S., Sarkar, S. H., & Sarkar, F. H. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.10.005 · Cited by 423 · cited 1×
“gov/) encodes a 411 amino acid serine protease that consists of two α and two anti-parallel β strands [19].”
BackgroundThe Urokinase Plasminogen Activator System: Role in Malignancy
Duffy, M. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043453559 · Cited by 400 · cited 2×
“Its main components include the plasminogen activators (uPA, urokinase plasminogen activator; tPA, tissue plasminogen activator), the cell membrane receptor for uPA (uPAR), the plasminogen activator inhibitors (PAI-1, plasminogen activator inhibitor 1; PAI-2, plasminogen activator inhibitor 2) and plasmin (Figure 1) […”
BackgroundThe urokinase plasminogen activator system: a target for anti-cancer therapy
Ulisse, S., Baldini, E., Sorrenti, S., & D'Armiento, M. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909787314002 · Cited by 312
Cancer invasion and metastasis: changing views
Duffy, M., McGowan, P., & Gallagher, W. (2008) · The Journal of Pathology · doi:10.1002/path.2282 · Cited by 302 · cited 1×
“However, most of the studies conducted to date, in several cancer types, indicate that SERPINE1 expression is associated with poor outcome and increased risk of metastasis [56].”
ResultDuffy, M. J., McGowan, P. M., Harbeck, N., Thomssen, C., & Schmitt, M. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0428-4 · Cited by 273 · cited 1×
“com/oncotarget node negative breast cancer [143-146].”
The multiple roles for Sox2 in stem cell maintenance and tumorigenesis
Liu, K., Lin, B., Zhao, M., Yang, X., Chen, M., Gao, A., Liu, F., Que, J., & Lan, X. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.02.013 · Cited by 263 · cited 1×
“The overexpression of SOX2, one of the main regulators of self-renewal in adult tissues, has also been associated with the development of different types of squamous cell carcinomas such as lung, esophagus and nasopharyngeal carcinomas [8, 99].”
BackgroundAguirre Ghiso, J. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205342 · Cited by 230
Epithelial to mesenchymal transition in head and neck squamous cell carcinoma
Smith, A., Teknos, T. N., & Pan, Q. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2012.10.009 · Cited by 226 · cited 1×
“SERPINE1 is directly connected with the epithelialmesenchymal transition (EMT) and the acquisition of stemness, two biological processes that are essential to control the transition from the proliferative to the invasive tumor phenotype [60, 93-97].”
BackgroundGötte, M., Mohr, C., Koo, C.-Y., Stock, C., Vaske, A.-K., Viola, M., Ibrahim, S. A., Peddibhotla, S., Teng, Y. H.-F., Low, J.-Y., et al. (2010) · Oncogene · doi:10.1038/onc.2010.386 · Cited by 220 · cited 1×
“com/oncotarget described as a target for the miR-145 [49-51].”
BackgroundGutierrez, L. S., Schulman, A., Brito-Robinson, T., Noria, F., Ploplis, V. A., & Castellino, F. (2000) · PubMed · Cited by 217
Impaired Notch Signaling Promotes De novo Squamous Cell Carcinoma Formation
Proweller, A., Tu, L., Lepore, J. J., Cheng, L., Lu, M. M., Seykora, J., Millar, S. E., Pear, W. S., & Parmacek, M. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0793 · Cited by 213 · cited 1×
“Notch signaling is a crucial regulator of stem cell renewal and promotes terminal differentiation of keratinocytes through the expression of p21 and caspase-3 [103-105].”
BackgroundDegryse, B., Neels, J. G., Czekay, R.-P., Aertgeerts, K., Kamikubo, Y.-I., & Loskutoff, D. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313004200 · Cited by 201
PAI-1: An Integrator of Cell Signaling and Migration
Czekay, R.-P., Wilkins-Port, C. E., Higgins, S. P., Freytag, J., Overstreet, J. M., Klein, R. M., Higgins, C. E., Samarakoon, R., & Higgins, P. J. (2011) · International Journal of Cell Biology · doi:10.1155/2011/562481 · Cited by 189 · cited 2×
“The results reported to date suggest that SERPINE1 expression could increase cell migration and simultaneously reduce cell proliferation [62, 90].”
BackgroundOkuyama, R., Nguyen, B.-C., Talora, C., Ogawa, E., di Vignano, A. T., Lioumi, M., Chiorino, G., Tagami, H., Woo, M., & Dotto, G. P. (2004) · Developmental Cell · doi:10.1016/s1534-5807(04)00098-x · Cited by 186 · cited 1×
“Notch signaling is a crucial regulator of stem cell renewal and promotes terminal differentiation of keratinocytes through the expression of p21 and caspase-3 [103-105].”
BackgroundThe Plasminogen Activator System and Cancer
McMahon, B. J., & Kwaan, H. C. (2007) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000175156 · Cited by 177 · cited 1×
“The uPA/uPAR interaction on the cell surface induces conformational changes that facilitate the formation of a new complex with integrins and with several ECM proteins such as vitronectin [23, 24].”
BackgroundJo, M., Lester, R. D., Montel, V., Eastman, B., Takimoto, S., & Gonias, S. L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.023960 · Cited by 175 · cited 1×
“Changes in cell adhesion and cytoskeletal remodeling, experienced during the EMT-process, increase tumor cell plasticity and drug resistance, effects that correlate with an increase in the expression of uPAR and SERPINE1 [106, 107].”
BackgroundCell adhesion molecules and their relation to (cancer) cell stemness
Farahani, E., Patra, H. K., Jangamreddy, J. R., Rashedi, I., Kawalec, M., Rao Pariti, R. K., Batakis, P., & Wiechec, E. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu045 · Cited by 174
Harbeck, N., Schmitt, M., Meisner, C., Friedel, C., Untch, M., Schmidt, M., Sweep, C. G. J., Lisboa, B. W., Lux, M. P., Beck, T., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.01.007 · Cited by 169
Nagata, M., Fujita, H., Ida, H., Hoshina, H., Inoue, T., Seki, Y., Ohnishi, M., Ohyama, T., Shingaki, S., Kaji, M., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.11283 · Cited by 167 · cited 1×
“Several studies showed that uPA or uPAR expression is associated with higher T stage, low grade of differentiation and the presence of lymph node metastasis [27, 117, 134, 139].”
BackgroundCell polarity signaling in the plasticity of cancer cell invasiveness
Gandalovičová, A., Vomastek, T., Rösel, D., & Brábek, J. (2016) · Oncotarget · doi:10.18632/oncotarget.7214 · Cited by 165
Advances and applications of oral cancer basic research
da Silva, S. D., Ferlito, A., Takes, R. P., Brakenhoff, R. H., Valentin, M. D., Woolgar, J. A., Bradford, C. R., Rodrigo, J. P., Rinaldo, A., Hier, M., et al. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.07.004 · Cited by 164 · cited 1×
“An appropriate classification would make it possible to optimize and rationalize treatment, management and HNSCC patient care after diagnosis [10, 11].”
BackgroundPlasminogen Activator Inhibitor-1 Protects Endothelial Cells from FasL-Mediated Apoptosis
Bajou, K., Peng, H., Laug, W. E., Maillard, C., Noel, A., Foidart, J. M., Martial, J. A., & DeClerck, Y. A. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.08.012 · Cited by 161 · cited 2×
“Thus, SERPINE1 over-expression has an antiapoptotic effect [15, 59, 85, 86] that is mainly associated with the inhibition of Fas/Fas-L mediated apoptosis [68, 87].”
BackgroundNovel markers for poor prognosis in head and neck cancer
Chin, D., Boyle, G. M., Williams, R. M., Ferguson, K., Pandeya, N., Pedley, J., Campbell, C. M., Theile, D. R., Parsons, P. G., & Coman, W. B. (2005) · International Journal of Cancer · doi:10.1002/ijc.20608 · Cited by 159 · cited 3×
“Most analyses conducted in head and neck cancer have concluded that the expression of uPA and uPAR is also associated with a poor clinical outcome [128, 140, 141] (Table 1).”
BackgroundFink, T., Kazlauskas, A., Poellinger, L., Ebbesen, P., & Zachar, V. (2002) · Blood · doi:10.1182/blood.v99.6.2077 · Cited by 151 · cited 1×
“Its expression could also be modulated by several transcription factors such as SP1, AP1, SMAD proteins, TGF-β1, and p53 [44-46].”
BackgroundDeclerck, P. J., Mol, M. D., Vaughan, D. E., & Collen, D. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49751-2 · Cited by 149 · cited 1×
“A non-inhibitory substrate form of SERPINE1 that could be cleaved by PAs has also been described [54].”
BackgroundCecco, L. D., Nicolau, M., Giannoccaro, M., Daidone, M. G., Bossi, P., Locati, L. D., Licitra, L. F., & Canevari, S. (2015) · Oncotarget · doi:10.18632/oncotarget.3301 · Cited by 148
Kates, R. E., Gauger, K., Willems, A., Kiechle, M. B., Magdolen, V., Schmitt, M., & Harbeck, N. (2004) · Thrombosis and Haemostasis · doi:10.1160/th03-12-0798 · Cited by 147 · cited 1×
“SERPINE1 is the main inhibitor of the uPA/uPAR complex, which induces its internalization through a process mediated by the lipoprotein receptor protein-1 (LRP1 receptor) [55].”
BackgroundFukuda, K., Sakakura, C., Miyagawa, K., Kuriu, Y., Kin, S., Nakase, Y., Hagiwara, A., Mitsufuji, S., Okazaki, Y., Hayashizaki, Y., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602187 · Cited by 144 · cited 1×
“In head and neck and oesophageal cancer cells, uPA and SERPINE1 expression are upregulated after irradiation or reactive oxygen species exposure [75-79].”
BackgroundDatta, P. K., Blake, M. C., & Moses, H. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000508200 · Cited by 143 · cited 1×
“The EMT process is associated with the activation of the TGF-β pathway which also induces SERPINE1 activation [98].”
BackgroundIdentification of uPAR-positive Chemoresistant Cells in Small Cell Lung Cancer
Gutova, M., Najbauer, J., Gevorgyan, A., Metz, M. Z., Weng, Y., Shih, C.-C., & Aboody, K. S. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000243 · Cited by 141 · cited 1×
“For instance, the uPAR expression has been associated with multidrug resistance in small cell lung cancer cells [72].”
BackgroundCraen, B. V. D., Declerck, P. J., & Gils, A. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.06.023 · Cited by 140 · cited 3×
“Thus, SERPINE1 over-expression has an antiapoptotic effect [15, 59, 85, 86] that is mainly associated with the inhibition of Fas/Fas-L mediated apoptosis [68, 87].”
BackgroundAn updated overview of HPV-associated head and neck carcinomas
Zaravinos, A. (2014) · Oncotarget · doi:10.18632/oncotarget.1934 · Cited by 134
The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer
Villadsen, S. B., Bramsen, J. B., Ostenfeld, M. S., Wiklund, E. D., Fristrup, N., Gao, S., Hansen, T. B., Jensen, T. I., Borre, M., Orntoft, T. F., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.520 · Cited by 128 · cited 1×
“com/oncotarget described as a target for the miR-145 [49-51].”
BackgroundSchmalbach, C. E., Chepeha, D. B., Giordano, T. J., Rubin, M. A., Teknos, T. N., Bradford, C. R., Wolf, G. T., Kuick, R. D., Misek, D. E., Trask, D. K., et al. (2004) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.130.3.295 · Cited by 115 · cited 1×
“In microarray gene expression studies, SERPINE1 expression has been identified as a HNSCC marker [109, 111, 121-123].”
BackgroundComprehensive expression profiling of microRNAs in laryngeal squamous cell carcinoma
Cao, P., Zhou, L., Zhang, J., Zheng, F., Wang, H., Ma, D., & Tian, J. (2012) · Head & Neck · doi:10.1002/hed.23011 · Cited by 104 · cited 1×
“com/oncotarget described as a target for the miR-145 [49-51].”
BackgroundLRP-1 Promotes Cancer Cell Invasion by Supporting ERK and Inhibiting JNK Signaling Pathways
Langlois, B., Perrot, G., Schneider, C., Henriet, P., Emonard, H., Martiny, L., & Dedieu, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011584 · Cited by 102 · cited 2×
“In thyroid cancer cells, LRP1 activates ERK and inhibits JNKdependent pathways, which maintain the invasive capacity of tumor cells [65].”
BackgroundClinical significance of head and neck squamous cell cancer biomarkers
Polanska, H. H., Raudenská, M., Gumulec, J., Sztalmachová, M., Adam, V., Kizek, R., & Masařík, M. (2014) · Oral Oncology · doi:10.1016/j.oraloncology.2013.12.008 · Cited by 101 · cited 1×
“An appropriate classification would make it possible to optimize and rationalize treatment, management and HNSCC patient care after diagnosis [10, 11].”
BackgroundWebb, D. J., Thomas, K. S., & Gonias, S. L. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.152.4.741 · Cited by 100 · cited 1×
“These findings are in agreement with several studies conducted in endothelial cells, fibrosarcoma and breast cancer cells indicating that SERPINE1 overexpression increases tumor cell migration and invasion through the activation of the PI3K-Akt pathway [63, 64].”
ResultPavón, M. Á., Arroyo‐Solera, I., Tellez-Gabriel, M., León, X., Porcuna, D. V., López, M., Gallardo, A., Céspedes, M. V., Casanova, I., Pousa, A. L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5032 · Cited by 98 · cited 17×
“SERPINE1 expression has also been associated with tumor cell migration and invasion in head and neck cancer cells [9, 61, 62].”
InfluentialSelf-citationGils, A., & Declerck, P. J. (2004) · Thrombosis and Haemostasis · doi:10.1160/th03-12-0764 · Cited by 93 · cited 1×
“Its active conformation inhibits tPA and uPA forming a complex with each enzyme, whereas its latent form does not react with their target proteinases [53].”
BackgroundProtumorigenic Activity of Plasminogen Activator Inhibitor-1 Through an Antiapoptotic Function
Hua, F., Placencio, V. R., & DeClerck, Y. A. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs377 · Cited by 92 · cited 4×
“In this sense, the antitumor activity of several small molecules inhibitors of SERPINE1, initially developed as antithrombotic agents, is currently being evaluated [87, 147-150].”
BackgroundInfluentialComponents of the Plasminogen-Plasmin System as Biologic Markers for Cancer
McMahon, B. J., & Kwaan, H. C. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-7215-0_10 · Cited by 89 · cited 1×
“A high expression of uPA/ uPAR and SERPINE1 has been observed in numerous cancer types, being associated with poor patient prognosis [12, 18].”
BackgroundJo, M., Eastman, B. M., Webb, D. L., Stoletov, K., Klemke, R., & Gonias, S. L. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1936 · Cited by 87 · cited 1×
“uPAR and uPA signaling could also contribute to cancer stemness, as it has been demonstrated in breast and pancreatic cancer cells [112, 113].”
BackgroundLiu, C., Liu, T., Kuo, L., Cheng, H., Chu, T., Chang, K., & Lin, S. (2008) · The Journal of Pathology · doi:10.1002/path.2306 · Cited by 85 · cited 1×
“In microarray gene expression studies, SERPINE1 expression has been identified as a HNSCC marker [109, 111, 121-123].”
BackgroundSakamoto, K., Fujii, T., Kawachi, H., Miki, Y., Omura, K., Morita, K.-I., Kayamori, K., Katsube, K., & Yamaguchi, A. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.9 · Cited by 85 · cited 1×
“It would be interesting to explore if this effect is also present in HNSCC, as a high percentage of inactivating mutations in Notch has been observed in this tumor type [101, 102].”
BackgroundThe Apparent uPA/PAI-1 Paradox in Cancer: More than Meets the Eye
Mazar, A. P., McMahon, B. J., & Kwaan, H. C. (2013) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0033-1338127 · Cited by 83 · cited 1×
“The uPA/uPAR interaction on the cell surface induces conformational changes that facilitate the formation of a new complex with integrins and with several ECM proteins such as vitronectin [23, 24].”
BackgroundKoyanagi, S., Kuramoto, Y., Kimura, M., Oda, M., Kozako, T., Hayashida, S., Shimeno, H., & Soeda, S. (2008) · Thrombosis and Haemostasis · doi:10.1160/th08-04-0259 · Cited by 82 · cited 1×
“Thus, SERPINE1 over-expression has an antiapoptotic effect [15, 59, 85, 86] that is mainly associated with the inhibition of Fas/Fas-L mediated apoptosis [68, 87].”
BackgroundSimone, T. M., Higgins, C. E., Czekay, R.-P., Law, B. K., Higgins, S. P., Archambeault, J., Kutz, S. M., & Higgins, P. J. (2014) · Advances in Wound Care · doi:10.1089/wound.2013.0512 · Cited by 82
Nozaki, S., Endo, Y., Kawashiri, S., Nakagawa, K., Yamamoto, E., Yonemura, Y., & Sasaki, T. (1998) · Oral Oncology · doi:10.1016/s1368-8375(97)00028-6 · Cited by 82 · cited 7×
“Pavon et al 2015 [62] Pasini et al 2001 [117] Speleman et al 2007 [118] Yasuda et al 1997 [127] Lindberg et al 2006 [116] Nozaki et al 1998 [27] Strojan et al 1998 [124] Chin et al 2005 [128] Huang et al 2014 [84] Magnussen et al 2014[130] Dhanda et al 2014 [61] Hundsdorfer et al 2005 [131] Strojan et al 2000 [141] Yo…”
BackgroundResultInfluentialFibronectin 1 is a potential biomarker for radioresistance in head and neck squamous cell carcinoma
Jerhammar, F., Ceder, R., Garvin, S., Grenman, R. A., Grafström, R. C., & Roberg, K. B. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.12.13432 · Cited by 81 · cited 1×
“In head and neck and oesophageal cancer cells, uPA and SERPINE1 expression are upregulated after irradiation or reactive oxygen species exposure [75-79].”
BackgroundDhanda, J., Triantafyllou, A. G., Liloglou, T., Kalirai, H., Lloyd, B. H., Hanlon, R., Shaw, R., Sibson, D. R., & Risk, J. M. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.500 · Cited by 81 · cited 4×
“Pavon et al 2015 [62] Pasini et al 2001 [117] Speleman et al 2007 [118] Yasuda et al 1997 [127] Lindberg et al 2006 [116] Nozaki et al 1998 [27] Strojan et al 1998 [124] Chin et al 2005 [128] Huang et al 2014 [84] Magnussen et al 2014[130] Dhanda et al 2014 [61] Hundsdorfer et al 2005 [131] Strojan et al 2000 [141] Yo…”
BackgroundInfluentialGomes-Giacoia, E., Miyake, M., Goodison, S., & Rosser, C. J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0500 · Cited by 78 · cited 2×
“In vitro and in vivo xenografts models have shown an effect for these inhibitors on angiogenesis, apoptosis induction and tumor growth [87, 154-158].”
BackgroundPinto, E. B., Sawazaki‐Calone, Í., Macedo, C. C. S., Carnielli, C. M., de Oliveira, C. E., Rodrigues, P. C., Rangel, A. L. C. A., dos Santos, J. N., Risteli, J., Graner, E., et al. (2016) · Tumor Biology · doi:10.1007/s13277-015-4629-y · Cited by 78
Hundsdörfer, B., Zeilhofer, H., Bock, K., Dettmar, P., Schmitt, M., Kolk, A., Pautke, C., & Horch, H. (2005) · Journal of Cranio-Maxillofacial Surgery · doi:10.1016/j.jcms.2004.12.005 · Cited by 77 · cited 2×
“Pavon et al 2015 [62] Pasini et al 2001 [117] Speleman et al 2007 [118] Yasuda et al 1997 [127] Lindberg et al 2006 [116] Nozaki et al 1998 [27] Strojan et al 1998 [124] Chin et al 2005 [128] Huang et al 2014 [84] Magnussen et al 2014[130] Dhanda et al 2014 [61] Hundsdorfer et al 2005 [131] Strojan et al 2000 [141] Yo…”
BackgroundShimada, T., Nakamura, H., Yamashita, K., Kawata, R., Murakami, Y., Fujimoto, N., Sato, H., Seiki, M., & Okada, Y. (2000) · Clinical & Experimental Metastasis · doi:10.1023/a:1006749501682 · Cited by 73 · cited 1×
“Plasmin cleaves a range of ECM proteins, such laminin and fibrin, and also activates metalloproteinases, such as the MMP2, previously associated with an increase of head and neck cancer cell invasion and metastasis [33-35].”
BackgroundBao, Y.-N., Cao, X., Luo, D., Sun, R., Peng, L.-X., Wang, L., Yan, Y., Zheng, L.-S., Xie, P., Cao, Y., et al. (2014) · Cell Cycle · doi:10.4161/cc.28921 · Cited by 72
Urokinase-Type Plasminogen Activator System in Breast Cancer
Gelder, M. E. M., Look, M. P., Peters, H. A., Schmitt, M., Brünner, N., Harbeck, N., Klijn, J. G. M., & Foekens, J. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3848 · Cited by 70
Leik, C. E., Su, E. J., Nambi, P., Crandall, D., & Lawrence, D. A. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02244.x · Cited by 70 · cited 1×
“In vitro and in vivo xenografts models have shown an effect for these inhibitors on angiogenesis, apoptosis induction and tumor growth [87, 154-158].”
BackgroundMéndez, E., Houck, J. R., Doody, D. R., Fan, W., Lohavanichbutr, P., Rue, T. C., Yueh, B., Futran, N. D., Upton, M. P., Farwell, D. G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1816 · Cited by 68 · cited 1×
“In microarray gene expression studies, SERPINE1 expression has been identified as a HNSCC marker [109, 111, 121-123].”
BackgroundLindberg, P., Larsson, Å., & Nielsen, B. S. (2006) · International Journal of Cancer · doi:10.1002/ijc.21568 · Cited by 66 · cited 5×
“Pavon et al 2015 [62] Pasini et al 2001 [117] Speleman et al 2007 [118] Yasuda et al 1997 [127] Lindberg et al 2006 [116] Nozaki et al 1998 [27] Strojan et al 1998 [124] Chin et al 2005 [128] Huang et al 2014 [84] Magnussen et al 2014[130] Dhanda et al 2014 [61] Hundsdorfer et al 2005 [131] Strojan et al 2000 [141] Yo…”
BackgroundInfluentialWilkins-Port, C. E., Ye, Q., Mazurkiewicz, J. E., & Higgins, P. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0043 · Cited by 64 · cited 1×
“In normal and transformed human keratinocytes, SERPINE1 is up-regulated in response to EGFR and TGF-β and is associated with an increase in cell migration and invasion [58-60].”
BackgroundBalsara, R. D., Castellino, F., & Ploplis, V. A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512819200 · Cited by 63 · cited 1×
“These findings are in agreement with several studies conducted in endothelial cells, fibrosarcoma and breast cancer cells indicating that SERPINE1 overexpression increases tumor cell migration and invasion through the activation of the PI3K-Akt pathway [63, 64].”
ResultAsuthkar, S., Stepanova, V. V., Lebedeva, T., Holterman, A. L., Estes, N. C., Cines, D. B., Rao, J. S., & Gondi, C. S. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e12-04-0306 · Cited by 61 · cited 1×
“uPAR and uPA signaling could also contribute to cancer stemness, as it has been demonstrated in breast and pancreatic cancer cells [112, 113].”
BackgroundPlasminogen activator inhibitor-1 inhibitors: a patent review (2006 – present)
Fortenberry, Y. M. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.782393 · Cited by 61 · cited 1×
“In this sense, the antitumor activity of several small molecules inhibitors of SERPINE1, initially developed as antithrombotic agents, is currently being evaluated [87, 147-150].”
BackgroundThe effect of plasminogen activator inhibitor type 1 on apoptosis
Chen, Y., Sobel, B. E., & Schneider, D. J. (2008) · Thrombosis and Haemostasis · doi:10.1160/th08-04-0234 · Cited by 59 · cited 2×
“Thus, SERPINE1 over-expression has an antiapoptotic effect [15, 59, 85, 86] that is mainly associated with the inhibition of Fas/Fas-L mediated apoptosis [68, 87].”
BackgroundInhibitors of the Protease Domain of Urokinase-Type Plasminogen Activator
Rockway, T. W., Nienaber, V. L., & Giranda, V. L. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023392676 · Cited by 59 · cited 1×
“In this sense, the antitumor activity of several small molecules inhibitors of SERPINE1, initially developed as antithrombotic agents, is currently being evaluated [87, 147-150].”
BackgroundWykosky, J., Hu, J., Gomez, G. G., Taylor, T. E., Villa, G. R., Pizzo, D. P., VandenBerg, S. R., Thorne, A. H., Chen, C. C., Mischel, P. S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2004 · Cited by 58 · cited 1×
“com/oncotarget [81].”
Rømer, M. U., Larsen, L., Offenberg, H., Brünner, N., & Lademann, U. A. (2008) · Neoplasia · doi:10.1593/neo.08486 · Cited by 58
Urokinase receptor and resistance to targeted anticancer agents
Gonias, S. L., & Hu, J. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00154 · Cited by 57 · cited 2×
“The plasminogen activator system proteins have been also associated with resistance to targeted therapies [71].”
BackgroundGörögh, T., Beier, U. H., Bäumken, J., Meyer, J. E., Hoffmann, M., Gottschlich, S., & Maune, S. (2005) · Head & Neck · doi:10.1002/hed.20298 · Cited by 56 · cited 1×
“Plasmin cleaves a range of ECM proteins, such laminin and fibrin, and also activates metalloproteinases, such as the MMP2, previously associated with an increase of head and neck cancer cell invasion and metastasis [33-35].”
BackgroundPlacencio, V. R., Ichimura, A., Miyata, T., & DeClerck, Y. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133786 · Cited by 52 · cited 1×
“In vitro and in vivo xenografts models have shown an effect for these inhibitors on angiogenesis, apoptosis induction and tumor growth [87, 154-158].”
BackgroundShi, Z., & Stack, M. S. (2007) · Biochemical Journal · doi:10.1042/bj20071037 · Cited by 50 · cited 2×
“The uPA/uPAR complex expression plays a significant role on the invasive and metastatic potential of HNSCC [22, 26-28] (Figure 2).”
BackgroundFrederickson, M., Callaghan, O., Chessari, G., Congreve, M., Cowan, S., Matthews, J. E., McMenamin, R. L., Smith, D.-M., Vinković, M., & Wallis, N. G. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm701359z · Cited by 49 · cited 1×
“Inhibitors of uPAR or uPA are also being developed and tested as antitumor agents in patients with breast, pancreatic and head and neck cancer in phase I-II trials [46, 159-162].”
BackgroundStrojan, P., Budihna, M., Šmid, L. M., Vrhovec, I., & Skrk, J. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00029-x · Cited by 46 · cited 4×
“Pavon et al 2015 [62] Pasini et al 2001 [117] Speleman et al 2007 [118] Yasuda et al 1997 [127] Lindberg et al 2006 [116] Nozaki et al 1998 [27] Strojan et al 1998 [124] Chin et al 2005 [128] Huang et al 2014 [84] Magnussen et al 2014[130] Dhanda et al 2014 [61] Hundsdorfer et al 2005 [131] Strojan et al 2000 [141] Yo…”
BackgroundInfluentialSimone, T. M., Longmate, W. M., Law, B. K., & Higgins, P. J. (2014) · Advances in Wound Care · doi:10.1089/wound.2014.0611 · Cited by 44 · cited 3×
“During the process of wound healing, TGF-β induces the expression of SERPINE1 in leading edge keratinocytes, which stimulates cell migration and re-epithelization [16].”
BackgroundPlasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression.
Hasina, R., Hulett, K., Bicciato, S., Bello, C. D., Petruzzelli, G. J., & Lingen, M. W. (2003) · PubMed · Cited by 44
He, Y., Shao, F., Pi, W., Shi, C., Chen, Y., Gong, D.-P., Wang, B., Cao, Z., & Tang, K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146530 · Cited by 44 · cited 2×
“HNSCC studies showed that the expression of uPA and uPAR is also commonly higher in tumor tissue than in normal tissue [114, 115, 117, 119, 127, 133-137].”
BackgroundTakes, R. P., Rinaldo, A., Rodrigo, J. P., Devaney, K. O., Fagan, J. J., & Ferlito, A. (2008) · Head & Neck · doi:10.1002/hed.20759 · Cited by 43
Invasive oral cancer stem cells display resistance to ionising radiation
Gemenetzidis, E., Gammon, L., Biddle, A., Emich, H., & Mackenzie, I. C. (2015) · Oncotarget · doi:10.18632/oncotarget.6268 · Cited by 43 · cited 1×
“SERPINE1 is directly connected with the epithelialmesenchymal transition (EMT) and the acquisition of stemness, two biological processes that are essential to control the transition from the proliferative to the invasive tumor phenotype [60, 93-97].”
BackgroundPacheco, M. M., Kowalski, L. P., Nishimoto, I. N., & Brentani, M. M. (2001) · Head & Neck · doi:10.1002/hed.10009 · Cited by 41 · cited 1×
“HNSCC studies showed that the expression of uPA and uPAR is also commonly higher in tumor tissue than in normal tissue [114, 115, 117, 119, 127, 133-137].”
BackgroundSamarakoon, R., Higgins, C. E., Higgins, S. P., & Higgins, P. (2009) · Journal of Oncology · doi:10.1155/2009/342391 · Cited by 37 · cited 3×
“Moreover, an association between the activation of EGFR signaling and SERPINE1 expression has also been described [60].”
BackgroundYu, X.-M., Jaskula‐Sztul, R., Georgen, M. R., Aburjania, Z., Somnay, Y. R., LEVERSON, G. E., Sippel, R. S., Lloyd, R. V., Johnson, B. P., & Chen, H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1749 · Cited by 37 · cited 1×
“have shown a link between SERPINE1 expression and Notch signaling in differentiated thyroid cancer [100].”
BackgroundZhou, H., Tang, Y., Liang, X., Yang, X., Yang, J., Zhu, G., Zheng, M. H., & Zhang, C. (2009) · International Journal of Cancer · doi:10.1002/ijc.24360 · Cited by 37 · cited 2×
“Moreover, the inhibition of uPAR has been associated with the downregulation of the multidrug resistance gene MDR1 [36].”
BackgroundAlbo, D., & Tuszynski, G. P. (2004) · Journal of Surgical Research · doi:10.1016/j.jss.2004.03.007 · Cited by 37 · cited 1×
“Thombospondin has also been associated with the activation of uPA and cell invasion in HNSCC cells [32].”
BackgroundPlasminogen activator system in oral squamous cell carcinoma
Baker, E. A., Leaper, D. J., Hayter, J. P., & Dickenson, A. J. (2007) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.bjoms.2007.04.021 · Cited by 35 · cited 2×
“HNSCC studies showed that the expression of uPA and uPAR is also commonly higher in tumor tissue than in normal tissue [114, 115, 117, 119, 127, 133-137].”
BackgroundPavón, M. Á., Parreño, M., Tellez-Gabriel, M., Sancho, F. J., López, M., Cespedes, M., Casanova, I., Pousa, A. L., Mangues, M. A., Quer, M., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs207 · Cited by 35 · cited 1×
“In microarray gene expression studies, SERPINE1 expression has been identified as a HNSCC marker [109, 111, 121-123].”
BackgroundSelf-citationSERPINB2 down‐regulation contributes to chemoresistance in head and neck cancer
Huang, Z., Li, H., Huang, Q., Chen, D., Han, J., Wang, L., Pan, C., Chen, W.-L., House, M. G., Nephew, K. P., et al. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22033 · Cited by 33 · cited 3×
“Pavon et al 2015 [62] Pasini et al 2001 [117] Speleman et al 2007 [118] Yasuda et al 1997 [127] Lindberg et al 2006 [116] Nozaki et al 1998 [27] Strojan et al 1998 [124] Chin et al 2005 [128] Huang et al 2014 [84] Magnussen et al 2014[130] Dhanda et al 2014 [61] Hundsdorfer et al 2005 [131] Strojan et al 2000 [141] Yo…”
BackgroundSkeldal, S., Krogdahl, A., Sørensen, J. A., Andreasen, P. A., & Gao, S. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-02-0114 · Cited by 33 · cited 1×
“SERPINE1 expression could be epigenetically modulated [47, 48] and it has been”
BackgroundMeyer, J. E., Brocks, C., Graefe, H., Mala, C., ns, N. T. A., rgle, M. B. U., Rempel, A., Rotter, N., Wollenberg, B., & Lang, S. (2008) · Breast Care · doi:10.1159/000151736 · Cited by 33 · cited 1×
“Inhibitors of uPAR or uPA are also being developed and tested as antitumor agents in patients with breast, pancreatic and head and neck cancer in phase I-II trials [46, 159-162].”
BackgroundNozaki, S., Endo, Y., Nakahara, H., Yoshizawa, K., Hashiba, Y., Kawashiri, S., Tanaka, A., Nakagawa, K., Matsuoka, Y., Kogo, M., et al. (2005) · Oral Oncology · doi:10.1016/j.oraloncology.2005.05.013 · Cited by 32 · cited 1×
“The inhibition of uPAR using antisense oligonucleotides reduces the invasiveness and the metastatic potential of head and neck cancer cells [41, 42].”
BackgroundMagnussen, S. N., Rikardsen, O., Hadler‐Olsen, E., Uhlin‐Hansen, L., Steigen, S. E., & Svineng, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101895 · Cited by 32 · cited 2×
“Pavon et al 2015 [62] Pasini et al 2001 [117] Speleman et al 2007 [118] Yasuda et al 1997 [127] Lindberg et al 2006 [116] Nozaki et al 1998 [27] Strojan et al 1998 [124] Chin et al 2005 [128] Huang et al 2014 [84] Magnussen et al 2014[130] Dhanda et al 2014 [61] Hundsdorfer et al 2005 [131] Strojan et al 2000 [141] Yo…”
BackgroundHuang, C., Yu, G., Wang, W., Liu, B., & Sun, Z. (2014) · PubMed Central · Cited by 31
Prognostic value of plasminogen activator inhibitor‐1 in head and neck squamous cell carcinoma
Speleman, L., Kerrebijn, J. D. F., Look, M. P., Meeuwis, C. A., Foekens, J. A., & Berns, E. M. J. J. (2006) · Head & Neck · doi:10.1002/hed.20527 · Cited by 30 · cited 4×
“Pavon et al 2015 [62] Pasini et al 2001 [117] Speleman et al 2007 [118] Yasuda et al 1997 [127] Lindberg et al 2006 [116] Nozaki et al 1998 [27] Strojan et al 1998 [124] Chin et al 2005 [128] Huang et al 2014 [84] Magnussen et al 2014[130] Dhanda et al 2014 [61] Hundsdorfer et al 2005 [131] Strojan et al 2000 [141] Yo…”
BackgroundInfluentialLee, C.-C., & Huang, T. (2005) · Cited by 29
Eastman, B. M., Jo, M., Webb, D. L., Takimoto, S., & Gonias, S. L. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.05.011 · Cited by 28 · cited 1×
“uPA, uPAR, and SERPINE1 have also been associated with the efficacy of tamoxifen treatment in breast cancer [73, 74].”
BackgroundSchilling, D., Bayer, C., Geurts-Moespot, A. J., Sweep, F. C. G. J., Pruschy, M. N., Mengele, K., Sprague, L., & Molls, M. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-143 · Cited by 28
Cancer stem-like cells in Epstein-Barr virus-associated nasopharyngeal carcinoma
Lun, S. W., Cheung, S., & Lo, K. W. (2014) · 癌症:英文版 · doi:10.5732/cjc.014.10081 · Cited by 28 · cited 3×
“A high percentage of patients develop recurrences, metastasis or secondary tumors after treatment, which results in a poor clinical outcome [4-8].”
BackgroundDu, B., Leung, H. T., Khan, K. M. F., Miller, C. G., Subbaramaiah, K., Falcone, D. J., & Dannenberg, A. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1388 · Cited by 27 · cited 1×
“We also found similar results by analyzing the expression data (RNA seq level 3 data) of HNSCC samples included in TCGA project (Figure 3 A) Tobacco smoke could induce the expression of uPA which is commonly overexpressed in premalignant and malignant lesions in the oral cavity [138].”
ResultEpigenetic alterations of the SERPINE1 gene in oral squamous cell carcinomas and normal oral mucosa
Gao, S., Nielsen, B. S., Krogdahl, A., Sørensen, J. A., Tagesen, J., Dabelsteen, S., Dabelsteen, E., & Andreasen, P. A. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20762 · Cited by 26 · cited 2×
“SERPINE1 expression could be epigenetically modulated [47, 48] and it has been”
BackgroundPAI-1 4G/5G Polymorphism Contributes to Cancer Susceptibility: Evidence from Meta-Analysis
Wang, S., Cao, Q., Wang, X., Li, B., Tang, M., Yuan, W., Fang, J., Qian, J., Qin, C., & Zhang, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056797 · Cited by 26
Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma
Waldron, N. N., Oh, S., & Vallera, D. A. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.06.002 · Cited by 25 · cited 1×
“In head and neck cancer cells, the combination of uPAR down-regulation and EGFR inhibition showed a synergistic anti-tumor effect [82, 83].”
BackgroundSimone, T. M., & Higgins, P. J. (2015) · Journal of Developmental Biology · doi:10.3390/jdb3010011 · Cited by 25 · cited 1×
“SERPINE1 regulates this process and the adhesion/deadhesion balance of cells to the ECM, which is essential to control and promote tumor cell migration [16, 17].”
BackgroundAbu‐Ali, S., Fotovati, A., & Shirasuna, K. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-47 · Cited by 23 · cited 1×
“In head and neck cancer cells, the combination of uPAR down-regulation and EGFR inhibition showed a synergistic anti-tumor effect [82, 83].”
BackgroundRosenthal, E. L., Hotary, K. B., Bradford, C. R., & Weiss, S. J. (1999) · Otolaryngology · doi:10.1016/s0194-5998(99)70217-2 · Cited by 23 · cited 1×
“Plasmin cleaves a range of ECM proteins, such laminin and fibrin, and also activates metalloproteinases, such as the MMP2, previously associated with an increase of head and neck cancer cell invasion and metastasis [33-35].”
BackgroundGhosh, S., Koblinski, J. E., Johnson, J. J., Liu, Y., Ericsson, A. C., Davis, J. W., Shi, Z., Ravosa, M. J., Crawford, S. E., Frazier, S. R., et al. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0045 · Cited by 23 · cited 1×
“A study conducted using an orthotopic murine model showed that the overexpression of uPAR in oral cancer cells generated infiltrative tumors with undefined margins and cytologic atypia [37].”
S35225 is a direct inhibitor of Plasminogen Activator Inhibitor type-1 activity in the blood
Rupin, A., Gaertner, R., Mennecier, P., Richard, I., Benoist, A., Nanteuil, G. D., & Verbeuren, T. J. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2007.11.006 · Cited by 22 · cited 1×
“In this sense, the antitumor activity of several small molecules inhibitors of SERPINE1, initially developed as antithrombotic agents, is currently being evaluated [87, 147-150].”
BackgroundLee, Y., Yu, C., Lan, C., Lee, C., Lee, H., Kuo, Y., Wang, P.-H., & Chang, W. (2015) · Head & Neck · doi:10.1002/hed.24124 · Cited by 22 · cited 6×
“The overexpression of SOX2, one of the main regulators of self-renewal in adult tissues, has also been associated with the development of different types of squamous cell carcinomas such as lung, esophagus and nasopharyngeal carcinomas [8, 99].”
BackgroundInfluentialArtman, M. T., Schilling, D., Gnann, J., Molls, M., Multhoff, G., & Bayer, C. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.08.035 · Cited by 22 · cited 1×
“In head and neck and oesophageal cancer cells, uPA and SERPINE1 expression are upregulated after irradiation or reactive oxygen species exposure [75-79].”
BackgroundJing, Y., Kovács, K., Kurisetty, V., Jiang, Z., Tsinoremas, N. F., & Merchan, J. R. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0145 · Cited by 18 · cited 1×
“Some groups showed that SERPINE1 expression increases cell proliferation, whereas others reported a reduction in cell proliferation [57, 70].”
BackgroundSimone, T. M. (2014) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.1000125 · Cited by 15 · cited 1×
“These specific inhibitors usually block the interaction between SERPINE1 and uPA and generate conformational changes that result in the irreversible conversion of SERPINE1 into its latent or cleaved forms [15, 147, 151-153].”
BackgroundHypoxia induces TFE3 expression in head and neck squamous cell carcinoma
Sun, Z., Yu, G., Huang, C., Bu, L., Liu, J., Ma, S., Zhang, W., Liu, B., & Zhang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7309 · Cited by 15 · cited 2×
“In this regard, the expression of SERPINE1 has been associated with the activation of hypoxia-related factors in head and neck cancer cells [52].”
TGF-β1 -Induced Expression of the Anti-Apoptotic PAI-1 Protein Requires EGFR Signaling
Higgins, S. P., Samarakoon, R., Higgins, C. E., Freytag, J., Wilkins-Port, C. E., & Higgins, P. J. (2009) · Cell Communication Insights · doi:10.4137/cci.s2775 · Cited by 13
Kolben, T., Kolben, T., Augustin, D., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3653-3 · Cited by 12 · cited 1×
“com/oncotarget node negative breast cancer [143-146].”
Nisa, L., Aebersold, D. M., Giger, R., Caversaccio, M. D., Borner, U., Medová, M., & Zimmer, Y. (2015) · Cancers · doi:10.3390/cancers7020585 · Cited by 9 · cited 1×
“HNSCC studies showed that the expression of uPA and uPAR is also commonly higher in tumor tissue than in normal tissue [114, 115, 117, 119, 127, 133-137].”
BackgroundLeto, G., Tumminello, F. M., Gebbia, V., Bazan, V., Tomasino, R. M., Dardanoni, G., & Russo, A. D. (2001) · The International Journal of Biological Markers · doi:10.1177/172460080101600404 · Cited by 5 · cited 1×
“HNSCC studies showed that the expression of uPA and uPAR is also commonly higher in tumor tissue than in normal tissue [114, 115, 117, 119, 127, 133-137].”
Background
Cited by
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Arasada, R. R., Shilo, K., Yamada, T., Zhang, J., Yano, S., Ghanem, R., Wang, W., Takeuchi, S., Fukuda, K., Katakami, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05626-2 · Cited by 93
Metadata
- Authors
- Pavón, M. A., Arroyo-Solera, I., Céspedes, M. V., Casanova, I., León, X., & Mangues, R.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-06-30
- Volume
- 7
- Issue
- 35
- Pages
- 57351-57366
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2471660791
- Cited by
- 163
- References
- 131
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.